ANAVEX LIFE SCIENCES CORP.

CIK 1314052 AVXL·Biological Products · All EDGAR filings ↗

Progression

2026-05-11 Late filing NT 10-Q
2026-08-28 Material weakness 10-K/A +109d

Refine

An amendment is grouped with the report it amends; every 12b-25 notice is one group

Material weakness high Filing comparison 2026-08-28

ANAVEX LIFE SCIENCES CORP. reported a material weakness in internal control

Internal control reported effective → Material weakness in internal control

A material weakness is a deficiency, or combination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in management’s assessment. The Company did not maintain effective Control Environment and Information and Communication elements of the COSO…

Evidence

Current state: material_weakness
Current state label: Material weakness in internal control
Direction: newly reported
Prior filed: 2025-11-25
Prior form: 10-K
Prior state: effective
Prior state label: Internal control reported effective
Remediation stated: Yes
Severity: high
Source: Item 9A internal control conclusion, compared with the prior filing
Why: The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.

Source filing ↗ Prior filing ↗

Late filing high Filing comparison 2026-08-10

ANAVEX LIFE SCIENCES CORP. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed 4 days before the statutory due date. other reports also outstanding

(the “Company”) is unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 (the “Form 10-Q”) by the prescribed August 10, 2026 due date without unreasonable effort and expense due to the circumstances described below. As previously disclosed in the Company’s Current Report on Form 8-K filed on May 6, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors (the “Board”) terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy. On…

Evidence

Anticipates significant change: No
Days past due date: -4
Other periodic reports filed: No
Routine: No
Severity: high
Source: Form 12b-25 (notification of late filing)
Stated reason: (the “Company”) is unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 (the “Form 10-Q”) by the prescribed August 10, 2026 due date without unreasonable effort and expense due to the circumstances described below. As previously disclosed in the Company’s Current Report on Form 8-K filed on May 6, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors (the “Board”) terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy. On…
Why: The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Late filing high Filing comparison 2026-05-11

ANAVEX LIFE SCIENCES CORP. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed 4 days before the statutory due date.

(the “Company”) is unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the “Form 10-Q”) by the prescribed May 11, 2026 due date without unreasonable effort and expense due to the circumstances described below. As previously disclosed in the Company’s Current Report on Form 8-K filed on May 6, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors (the “Board”) terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy. On…

Evidence

Anticipates significant change: No
Days past due date: -4
Other periodic reports filed: Yes
Routine: No
Severity: high
Source: Form 12b-25 (notification of late filing)
Stated reason: (the “Company”) is unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the “Form 10-Q”) by the prescribed May 11, 2026 due date without unreasonable effort and expense due to the circumstances described below. As previously disclosed in the Company’s Current Report on Form 8-K filed on May 6, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors (the “Board”) terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy. On…
Why: The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗